WO2000058005A3 - Immunadsorber zur sepsistherapie - Google Patents

Immunadsorber zur sepsistherapie Download PDF

Info

Publication number
WO2000058005A3
WO2000058005A3 PCT/DE2000/000927 DE0000927W WO0058005A3 WO 2000058005 A3 WO2000058005 A3 WO 2000058005A3 DE 0000927 W DE0000927 W DE 0000927W WO 0058005 A3 WO0058005 A3 WO 0058005A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunoadsorber
sepsis
sepsis therapy
therapy
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2000/000927
Other languages
English (en)
French (fr)
Other versions
WO2000058005A2 (de
Inventor
Hans-Werner Heinrich
Hans-Juergen Hahn
Udo Meyer
Peter Kruschke
Heinz-Juergen Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioserv AG
Original Assignee
Bioserv AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioserv AG filed Critical Bioserv AG
Priority to AT00929248T priority Critical patent/ATE233571T1/de
Priority to DE50001376T priority patent/DE50001376D1/de
Priority to AU47425/00A priority patent/AU760668B2/en
Priority to JP2000607750A priority patent/JP4307743B2/ja
Priority to IL14555700A priority patent/IL145557A/xx
Priority to US09/937,126 priority patent/US6881408B1/en
Priority to CA2366455A priority patent/CA2366455C/en
Priority to HK02104556.6A priority patent/HK1044115B/xx
Priority to EP00929248A priority patent/EP1163004B1/de
Publication of WO2000058005A2 publication Critical patent/WO2000058005A2/de
Publication of WO2000058005A3 publication Critical patent/WO2000058005A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Anesthesiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • External Artificial Organs (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Die Erfindung betrifft Immunadsorber zur Sepsistherapie, insbesondere zur Entfernung von Komplementfaktoren und Lipopolysacchariden (LPS) sowie ggf. von weiteren Sepsis-Mediatoren, wie z.B. TNF und Interleukinen aus Körperflüssigkeiten, Verfahren zu ihrer Herstellung und ihre Verwendung.
PCT/DE2000/000927 1999-03-26 2000-03-23 Immunadsorber zur sepsistherapie Ceased WO2000058005A2 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AT00929248T ATE233571T1 (de) 1999-03-26 2000-03-23 Immunadsorber zur sepsistherapie
DE50001376T DE50001376D1 (de) 1999-03-26 2000-03-23 Immunadsorber zur sepsistherapie
AU47425/00A AU760668B2 (en) 1999-03-26 2000-03-23 Immunoadsorber for use in sepsis therapy
JP2000607750A JP4307743B2 (ja) 1999-03-26 2000-03-23 敗血症療法のための免疫吸着剤
IL14555700A IL145557A (en) 1999-03-26 2000-03-23 Immunoabsorber for use in sepsis therapy
US09/937,126 US6881408B1 (en) 1999-03-26 2000-03-23 Immunoadsorber for use in sepsis therapy
CA2366455A CA2366455C (en) 1999-03-26 2000-03-23 Immunoadsorber for use in sepsis therapy
HK02104556.6A HK1044115B (en) 1999-03-26 2000-03-23 Immunoadsorber for use in sepsis therapy
EP00929248A EP1163004B1 (de) 1999-03-26 2000-03-23 Immunadsorber zur sepsistherapie

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19913707A DE19913707A1 (de) 1999-03-26 1999-03-26 Immunadsorber zur Sepsistherapie
DE19913707.2 1999-03-26

Publications (2)

Publication Number Publication Date
WO2000058005A2 WO2000058005A2 (de) 2000-10-05
WO2000058005A3 true WO2000058005A3 (de) 2001-03-29

Family

ID=7902471

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2000/000927 Ceased WO2000058005A2 (de) 1999-03-26 2000-03-23 Immunadsorber zur sepsistherapie

Country Status (12)

Country Link
US (1) US6881408B1 (de)
EP (1) EP1163004B1 (de)
JP (1) JP4307743B2 (de)
KR (1) KR100686364B1 (de)
CN (1) CN1160126C (de)
AT (1) ATE233571T1 (de)
AU (1) AU760668B2 (de)
CA (1) CA2366455C (de)
DE (2) DE19913707A1 (de)
ES (1) ES2193958T3 (de)
IL (1) IL145557A (de)
WO (1) WO2000058005A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829085B2 (en) * 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
DE10118446A1 (de) * 2001-04-12 2002-10-17 Thomas Hartung Prüfverfahren zur Untersuchung fließfähiger Medien auf Gehalte an mikrobiellen Toxinen
US20030215460A1 (en) * 2002-05-07 2003-11-20 Schall Thomas J. Methods and compositions for inducing an immune response
US7569025B2 (en) * 2002-04-02 2009-08-04 Scantibodies Laboratory, Inc. Methods and devices for treating severe peripheral bacterial infections
US8329169B2 (en) * 2003-05-15 2012-12-11 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
CA2535489C (en) 2003-08-14 2014-09-30 D. Collen Research Foundation Vzw Antibodies against factor viii with modified glycosylation in the variable region
MXPA06009805A (es) * 2004-02-27 2007-04-02 Vaxconsulting Peptidos de interleucina 1 beta y factor de necrosis tumoral alfa y metodo de tratamiento utilizando los mismos.
DE102004029573A1 (de) * 2004-06-18 2005-12-29 Gambro Lundia Ab MIF-Adsorbent
ITMI20041569A1 (it) * 2004-07-30 2004-10-30 Tecnogen Scpa "ligandi peptidici specifici per le immunoglobuline"
WO2006042507A1 (de) * 2004-10-20 2006-04-27 Adexter Technology Limited Immunadsorber für die behandlung von entzündungen
WO2007013945A2 (en) * 2005-07-20 2007-02-01 The Regents Of The University Of California Treating disorders associated with inflammation
WO2007024825A2 (en) * 2005-08-26 2007-03-01 Genway Biotech, Inc. Immunoaffinity separation and analysis compositions and methods
US8430831B2 (en) * 2009-02-25 2013-04-30 The Invention Science Fund I, Llc Device, system, and method for controllably reducing inflammatory mediators in a subject
DE102009034150A1 (de) 2009-07-20 2011-01-27 Fresenius Medical Care Deutschland Gmbh Adsorbens zur Adsorption von Hepcidin
EP2679302A1 (de) 2012-06-28 2014-01-01 Zentrum für biomedizinische Technologie der Donau- Universität Krems Selektives Sorptionsmittel für die extrakorporale Blutreinigung
EP3185926B1 (de) 2014-08-26 2018-11-28 3M Innovative Properties Company System zur entfernung von proinflammatorischen mediatoren sowie von granulozyten und monozyten aus blut
EP3477300A1 (de) 2017-10-25 2019-05-01 Euroimmun Medizinische Labordiagnostika AG Zellulose-basierter immunadsorber
US20190247560A1 (en) * 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
WO2021063708A1 (en) 2019-09-30 2021-04-08 Hemotune Ag Assembly for extracorporeal treatment of body fluids
CN113967367A (zh) * 2020-07-25 2022-01-25 苏州仝乾医疗科技有限公司 新冠病毒治疗用细胞因子抗体组合物及治疗用吸附剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300740A2 (de) * 1987-07-20 1989-01-25 Cefem A/S Monoklonale Antikörper gegen das Komplement C5A
GB2251187A (en) * 1989-08-10 1992-07-01 Celltech Ltd Pharmaceutical product for the treatment of sepsis
WO1994021124A1 (en) * 1993-03-16 1994-09-29 Applied Immune Sciences, Inc. Removal of selected factors from whole blood or its components
US5679775A (en) * 1995-04-27 1997-10-21 B. Braun Melsungen Ag. Process and device for the simultaneous extracorporeal elimination of tumour necrosis factor and bacterial lipopolysaccharides from whole blood and/or blood plasma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5626843A (en) * 1993-02-26 1997-05-06 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS, by removel of interferons, TNFs and receptors therefor
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
AU2191795A (en) 1994-03-23 1995-10-09 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5922690A (en) 1996-04-25 1999-07-13 Van Gorp; Cornelius L. Dermatan disulfate, an inhibitor of thrombin generation and activation
US6287516B1 (en) * 1998-07-10 2001-09-11 Immunocept, L.L.C. Hemofiltration systems, methods, and devices used to treat inflammatory mediator related disease
US6193681B1 (en) * 1998-09-14 2001-02-27 American Immuno Tech, Llc. Septicemia prevention and treatment system

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300740A2 (de) * 1987-07-20 1989-01-25 Cefem A/S Monoklonale Antikörper gegen das Komplement C5A
GB2251187A (en) * 1989-08-10 1992-07-01 Celltech Ltd Pharmaceutical product for the treatment of sepsis
WO1994021124A1 (en) * 1993-03-16 1994-09-29 Applied Immune Sciences, Inc. Removal of selected factors from whole blood or its components
US5679775A (en) * 1995-04-27 1997-10-21 B. Braun Melsungen Ag. Process and device for the simultaneous extracorporeal elimination of tumour necrosis factor and bacterial lipopolysaccharides from whole blood and/or blood plasma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOFFMANN J.N. ET AL: "Effect of hemofiltration on hemodynamics and systemic concentrations of anaphylatoxins and cytokines in human sepsis.", INTENSIVE CARE MEDICINE, (1996) 22/12 (1360-1367)., XP000939172 *

Also Published As

Publication number Publication date
ATE233571T1 (de) 2003-03-15
US6881408B1 (en) 2005-04-19
CN1346280A (zh) 2002-04-24
JP4307743B2 (ja) 2009-08-05
WO2000058005A2 (de) 2000-10-05
IL145557A0 (en) 2002-06-30
HK1044115A1 (en) 2002-10-11
CA2366455C (en) 2012-06-05
AU760668B2 (en) 2003-05-22
EP1163004B1 (de) 2003-03-05
DE19913707A1 (de) 2000-10-05
EP1163004A2 (de) 2001-12-19
AU4742500A (en) 2000-10-16
DE50001376D1 (de) 2003-04-10
IL145557A (en) 2005-09-25
KR20010112371A (ko) 2001-12-20
JP2002539910A (ja) 2002-11-26
KR100686364B1 (ko) 2007-02-23
CA2366455A1 (en) 2000-10-05
CN1160126C (zh) 2004-08-04
ES2193958T3 (es) 2003-11-16

Similar Documents

Publication Publication Date Title
WO2000058005A3 (de) Immunadsorber zur sepsistherapie
AU2002215230A1 (en) Internet commerce system and the method
AU2001274511A1 (en) Adsorbent, process for producing the same, and applications thereof
AU2001277901A1 (en) System and method for establishing business to business connections via the internet
AU2001288343A1 (en) Method and system for payment over the internet
AU2001230237A1 (en) Extracts from residues left in the production of wine
AU2001292353A1 (en) Multilayered metal laminate and process for producing the same
AU2001259795A1 (en) Technique for securely conducting online transactions
AU2002243216A1 (en) System for completing forms on the internet
AU2856499A (en) Novel substances kf-1040t4a, kf-1040t4b, kf-1040t5a and kf-1040t5b and process for producing the same
AU2001251584A1 (en) System for conducting business over the internet
ZA200102039B (en) Process for making snack foods having two or more filled axial cavities.
AU2002314790A1 (en) Method for immobilizing a biologic in a polyurethane-hydrogel composition, a composition prepared from the method, and biomedical applications
MXPA03005054A (es) Producto de inmovilizador de rodillo, formable a la medida, inmovilizador de rodilla y metodo.
MXPA03007408A (es) Proceso de polimerizacion.
WO2004006834A3 (en) Leflunomide analogs for treating rheumatoid arthritis
AU2001241171A1 (en) Solid electrolytic capacitor and method for producing the same
AU7424600A (en) Method for acquiring a certain product, such as a car, through the internet
AU2001289729A1 (en) Perfluoroalkyl-containing complexes comprising sugar residues, method for producing the same and use thereof
AU2002240161A1 (en) System and process for securitizing payments to third parties
AU2441699A (en) Method for payment via the internet
AU8972901A (en) Perfluoroalkyl-containing complexes comprising sugar residues, method for producing the same and use thereof
MXPA02012826A (es) Resinas epoxi y proceso para hacer las mismas.
AU2001272808A1 (en) The consignment sale method using internet
ZA200308166B (en) Extraction process.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00805568.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2366455

Country of ref document: CA

Ref document number: 2366455

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017012230

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 607750

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000929248

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 47425/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 09937126

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000929248

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017012230

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 2000929248

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 47425/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1020017012230

Country of ref document: KR